http://orcid.org/0000-0002-9538-0565
References
- Berezhkovskiy LM. (2007). The connection between the steady state (Vss) and terminal (Vβ) volumes of distribution in linear pharmacokinetics and the general proof that Vβ ≥ Vss. J Pharm Sci 96:1638–52.
- Camm AJ, Kirchhof P, Lip GY, et al. (2010). Guidelines for the management of atrial fibrillation: the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC). Eur Heart J 31:2369–429.
- Center for Drug Evaluation and Research (CDER). (2001). Guidance for industry, Bioanalytical method validation, US FDA. Available from: http://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm070107.pdf [last accessed 21 Nov 2016].
- Center for Drug Evaluation and Research (CDER). (2005). Guidance for industry, estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. US FDA. Available from: https://www.fda.gov/downloads/drugs/guidances/ucm078932.pdf [last accessed 19 Jul 2017].
- D’Argenio DZ, Schumitzky A, Wang X. (2009). ADAPT 5 user’s guide: pharmacokinetic/pharmacodynamic systems analysis software. Los Angeles (CA): Biomedical Simulations Resource.
- Dorian P. (2010). Clinical pharmacology of dronedarone: implications for the therapy of atrial fibrillation. J Cardiovasc Pharmacol Ther 15:15S–18S.
- Gough K, Hutchison M, Keene O, et al. (1995). Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inf J 29:1039–48.
- Hoy SM, Keam SJ. (2009). Dronedarone. Drugs 69:1647–63.
- Hummel J, McKendrick S, Brindley C, French R. (2009). Exploratory assessment of dose proportionality: review of current approaches and proposal for a practical criterion. Pharm Stat 8:38–49.
- Hynes BJ, Luck JC, Wolbrette DL, et al. (2005). A review of the pharmacokinetics, electrophysiology and clinical efficacy of dronedarone. Future Cardiol 1:135–44.
- January CT, Wann LS, Alpert JS, et al. (2014). 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130:e199–267.
- Jardan YA, Brocks DR. (2016). The pharmacokinetics of dronedarone in normolipidemic and hyperlipidemic rats. Biopharm Drug Dispos 37:345–51.
- Kathofer S, Thomas D, Karle CA. (2005). The novel antiarrhythmic drug dronedarone: comparison with amiodarone. Cardiovasc Drug Rev 23:217–30.
- Kim MS, Baek IH. (2018). Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats. Eur J Pharm Sci 111:13–19.
- Kletting P, Glatting G. (2009). Model selection for time-activity curves: the corrected Akaike information criterion and the F-test. Z Med Phys 19:200–6.
- Laughlin JC, Kowey PR. (2008). Dronedarone: a new treatment for atrial fibrillation. J Cardiovasc Electrophysiol 19:1220–6.
- Ludden TM, Beal SL, Sheiner LB. (1994). Comparison of the akaike information criterion, the schwarz criterion and the F test as guides to model selection. J Pharmacokinet Biopharm 22:431–45.
- Qiao H, Zhang X, Wang T, et al. (2014). Pharmacokinetics, biodistribution and bioavailability of isoliquiritigenin after intravenous and oral administration. Pharm Biol 52:228–36.
- Smith BP, Vandenhende FR, DeSante KA, et al. (2000). Confidence interval criteria for assessment of dose proportionality. Pharm. Res 17:1278–83.
- Sun W, Sarma JS, Singh BN. (1999). Electrophysiological effects of dronedarone (SR33589), a noniodinated benzofuran derivative, in the rabbit heart: comparison with amiodarone. Circulation 100:2276–81.
- Wang J, Li G, Rui T, et al. (2017). Pharmacokinetics of rosmarinic acid in rats by LC-MS/MS: absolute bioavailability and dose proportionality. RSC Adv 7:9057–63.